Journal profile · MEDICAL INFORMATICS-PHARMACOLOGY & PHARMACY
Therapeutic Innovation & Regulatory Science
ISSN 2168-4790 · eISSN 2168-4804 · Springer International Publishing · UNITED STATES · 6 issues per year · Founded 1997
Therapeutic Innovation & Regulatory Science: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.11; hybrid open access; APC about USD 4,090; median 155 days to acceptance (95 articles, last 24 months); 168 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Therapeutic Innovation & Regulatory Science is published by Springer International Publishing and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Health Systems, Economic Evaluations, Quality of Life, Statistical Methods in Clinical Trials and Pharmaceutical Economics and Policy, together about 39.9% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Therapeutic Innovation & Regulatory Science (TIRS) publishes peer-reviewed original research, review articles, commentaries, and letters to the editor on medical product discovery, development, regulation, access, and policy. As the official scientific journal of the Drug Information Association (DIA), TIRS provides a unique platform for researchers, regulators, developers, patient advocacy groups, payers, and other healthcare decision-makers from around the globe to convert scientific innovations and tools from across the entire medical product lifecycle into practical solutions that advance human health. The journal focuses on the following areas: Biostatistics Clinical Trials Product Development and Innovation Regulatory Science and Policy Medical Product Value, Pricing, and Payment Reforms Coverage and Access Policy Patient Engagement and Patient-Centered Product Development Diversity and Inclusion from early clinical development to access Pharmacovigilance and Product Safety Real World Evidence (RWE) Development and Use in Regulatory and Access Decision-Making This journal is a member of the Committee on Publication Ethics (COPE).
From the journal's Aims & Scope
Research area (LetPub): MEDICAL INFORMATICS-PHARMACOLOGY & PHARMACY
Editor-in-chief Gregory W. DanielPublisher website
Editorial board by country: 2 in mainland China (about 5%); most named United States 29, United Kingdom 4, Mainland China 2, Hong Kong, China 1, Australia 1 (37 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Health Systems, Economic Evaluations, Quality of LifeEconomics, Econometrics and Finance15.4%
- Statistical Methods in Clinical TrialsMathematics13.3%
- Pharmaceutical Economics and PolicyEconomics, Econometrics and Finance11.2%
- Biomedical Ethics and RegulationMedicine7.4%
- Ethics in Clinical ResearchMedicine6.8%
- Pharmaceutical studies and practicesMedicine5.2%
- Pharmaceutical industry and healthcarePharmacology, Toxicology and Pharmaceutics5.1%
- Pharmacovigilance and Adverse Drug ReactionsPharmacology, Toxicology and Pharmaceutics5.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medical Informatics | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medical Informatics | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medical Informatics | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbasePublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.11LetPub ·
- Impact factor (publisher) 2025
- 2.1Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.1Publisher website ·
- CiteScore 2026-06
- 4.3LetPub ·
- SJR 2026-06
- 0.9LetPub ·
- SNIP 2026-06
- 1.15LetPub ·
- h-index
- 12LetPub ·
- h-index
- 50OpenAlex ·
- i10-index
- 478OpenAlex ·
- 2-year mean citedness
- 2.18OpenAlex ·
- Self-citation rate
- 9.5%LetPub ·
- Share of gold OA articles
- 46.65%LetPub ·
Volume
- Articles per year
- 151LetPub ·
- Downloads per year (publisher) 2025
- 626,800Publisher website ·
Articles by year OpenAlex count · 1,874 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 145 | 55 | 32 |
| 2025 | 168 | 81 | 370 |
| 2024 | 132 | 69 | 570 |
| 2023 | 111 | 60 | 885 |
| 2022 | 134 | 82 | 1,567 |
| 2021 | 109 | 64 | 1,468 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
155 daysMedian, submission to acceptance · P25–P75 104 days – 211 days
- Acceptance to online
- median 11 days (95 articles)
- Submission to online
- median 179 days
- Sample
- 95 articles with submission and acceptance dates (347 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 19 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,090 / EUR 3,090 / GBP 2,690 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open access publishing
To find out more about publishing your work Open Access in Therapeutic Innovation & Regulatory Science, including information on fees, funding and licences, visit our Open access publishing page.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer International Publishing
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- 6 issues per year
- Founded
- 1997
- ISSN
- 2168-4790
- Electronic ISSN
- 2168-4804
- Latest issue on the website
- Volume 60, Issue 5 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Therapeutic Innovation & Regulatory Science
What CAS zone is Therapeutic Innovation & Regulatory Science in?
In the 2025 upgraded edition of the CAS Journal Ranking, Therapeutic Innovation & Regulatory Science is in Zone 4 of Medicine, and in Zone 4 of the minor category Medical Informatics / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Therapeutic Innovation & Regulatory Science?
The latest impact factor listed by LetPub is 2.11; CiteScore 4.3, h-index 50.
How long does peer review take at Therapeutic Innovation & Regulatory Science?
Based on the dates recorded on 95 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 155 days (interquartile range 104–211 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Therapeutic Innovation & Regulatory Science based?
Of the 37 board members whose country the journal's board page names, 2 (about 5%) are in mainland China; the countries named most often are United States (29), United Kingdom (4) and Mainland China (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Therapeutic Innovation & Regulatory Science?
According to LetPub and DOAJ records, Therapeutic Innovation & Regulatory Science is indexed in SCIE and Scopus. The journal's website also lists MEDLINE and Embase; that list has not been checked against each database.
Is Therapeutic Innovation & Regulatory Science open access, and what is the APC?
Therapeutic Innovation & Regulatory Science is a hybrid journal. For open-access publication: APC about USD 4,090.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .